GS 2: GovernanceGS 3: Science & TechnologyGS 2: Social JusticePrelimsGS 2: Government policies and interventions for development in various sectors
Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials Under Central Regulatory Oversight
Health Ministry proposes amending 2019 drug rules to bring antimicrobials under central oversight, combating AMR by ensuring quality, safety, and efficacy.
The Union Health Ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to include 'antimicrobials' in the definition of 'New Drug'.
This initiative aims to strengthen central regulatory oversight on antimicrobial manufacturing and combat Antimicrobial Resistance (AMR).
Under the proposed change, manufacturers will need permission from the Central Licensing Authority (CLA) before applying for a manufacturing license from State authorities.
The amendment addresses concerns regarding inadequate regulatory scrutiny, such as bioavailability/bioequivalence and stability studies, for antimicrobial products.
This move aligns with the G20 New Delhi Leaders’ Declaration, which emphasized addressing AMR through a One Health approach.
Detailed Insights:
The current absence of adequate assessments for antimicrobials can compromise their quality, safety, and efficacy, contributing to AMR.
Substandard or ineffective antimicrobials pose significant risks to patient safety by failing to treat infections and fostering drug resistance.
Bringing antimicrobials under the new drug regulatory framework will ensure uniform quality standards and rigorous testing nationwide.
This regulatory enhancement is crucial for preserving the effectiveness of existing antimicrobial treatments and safeguarding public health.
The draft notification has been issued for public and stakeholder feedback, allowing 30 days for objections and suggestions before finalization.
Key Concepts Involved:
Antimicrobial Resistance (AMR): The ability of microorganisms to withstand antimicrobial treatments, making infections difficult or impossible to treat.
New Drugs and Clinical Trials Rules, 2019: Regulations governing the approval, manufacture, and sale of new drugs and the conduct of clinical trials in India.
One Health approach: A collaborative, multi-sectoral, and trans-disciplinary approach recognizing the interconnectedness of human, animal, and environmental health.
Central Licensing Authority (CLA): The central regulatory body responsible for granting permissions for the manufacture and sale of drugs in India.